Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare services

被引:4
|
作者
Walker, Andrew [1 ]
机构
[1] Calderdale & Huddersfield NHS Fdn Trust, Dept Pharm, Huddersfield, W Yorkshire, England
关键词
Neurotrophic tyrosine receptor kinase; larotrectinib; entrectinib; neurotrophic tyrosine receptor kinase inhibitor; oncology; ETV6-NTRK3 GENE FUSION; CANCER; TROPOMYOSIN; THERAPIES; PATHOLOGY; ONCOGENE; TRK;
D O I
10.1177/1078155220959428
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neurotrophic tyrosine receptor kinase (NTRK) inhibitors represent the latest advancement as a treatment option in targeted therapies for malignant disease. NTRK gene fusions involving NTRK1, 2 or 3 are implicated as genetics drivers for a number of tumour types which arise within adult and paedatric patients. NTRK inhibitors (Larotrectinib and Entrectinib) are effective agents which have demonstrated clinical benefit in the treatment of NTRK fusion positive solid tumours. Larotrectinib represents the first targeted agent to receive approval from international authorisation and commissioning bodies for the treatment of a specific genetic expression indiscriminate of the site from which the tumour has arisen. As such NTRK inhibitors could pave the way for international healthcare bodies to adopt a similar approach for future targeted therapies thereby altering the manner in which healthcare providers and patients are able to access and utilise innovative, targeted treatment options in future. The potential implications of this new approach are likely to impact upon several aspects of the traditional authorisation and commissioning pathways with potential changes to the design of clinical trials, the review and approval process by regulatory bodies and immunohistopathology services.
引用
收藏
页码:2015 / 2019
页数:5
相关论文
共 50 条
  • [41] Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management
    Fancher, Karen M.
    Pappacena, Jeremy J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (04) : 507 - 515
  • [42] Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management
    Karen M. Fancher
    Jeremy J. Pappacena
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 507 - 515
  • [43] Intolerance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Definitions and Clinical Implications
    Pinilla-Ibarz, Javier
    Cortes, Jorge
    Mauro, Michael J.
    CANCER, 2011, 117 (04) : 688 - 697
  • [44] Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review
    Rambhatla, Anupama
    Strug, Michael R.
    De Paredes, Jessica Garcia
    Cordoba Munoz, Marcos I.
    Thakur, Mili
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2021, 38 (08) : 1897 - 1908
  • [45] Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors
    George Martin
    Dermatology and Therapy, 2023, 13 : 417 - 435
  • [46] Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review
    Shan Su
    Yi-Long Wu
    Journal of Hematology & Oncology, 10
  • [47] Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review
    Anupama Rambhatla
    Michael R. Strug
    Jessica Garcia De Paredes
    Marcos I. Cordoba Munoz
    Mili Thakur
    Journal of Assisted Reproduction and Genetics, 2021, 38 : 1897 - 1908
  • [48] Tyrosine Kinase Inhibitors and Solid Tumours: Case Report and Review of the Literature
    Roszkiewicz, F.
    Garidi, R.
    Vaida, I.
    Royer, B.
    Parcelier, A.
    Marolleau, J. P.
    Damaj, G.
    PHARMACOLOGY, 2009, 84 (01) : 38 - 41
  • [49] Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review
    Das, Anupam
    Sil, Abheek
    Khan, Ismat Ara
    Bandyopadhyay, Debabrata
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (06) : 599 - 608
  • [50] FMS-like tyrosine kinase 3 inhibitors: a patent review
    Lee, Jongkook
    Paek, Seung-Mann
    Han, Sun-Young
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (04) : 483 - 503